Eli Lilly and Company (LLY) News Today

Eli Lilly and Company (LLY) shares have seen mixed pressure today as investors weigh the company’s strong financing moves, encouraging trial and analyst updates, and growing GLP-1 competition from Novo Nordisk.

• Positive Sentiment: Lilly tapped the debt markets with a rare 40-year bond issue, attracting robust demand amid falling yields Eli Lilly Just Did What Almost No One Dares in 2025
• Positive Sentiment: Signed a $1.3 billion collaboration with Superluminal to leverage AI for future drug discovery Eli Lilly Signs $1.3 Billion Deal with Superluminal to Discover Future Drugs Using AI
• Positive Sentiment: Phase 3 TRAILBLAZER-ALZ 2 long-term extension data showed continued slowing of decline with Kisunla (donanemab) over three years Eli Lilly and Company (LLY) Announces Results From LTE of Phase 3 TRAILBLAZER-ALZ 2 Study
• Positive Sentiment: Management insiders, including the CEO, made significant share purchases, signaling confidence in valuation Eli Lilly: A Textbook Insider Buying Play
• Positive Sentiment: Cantor Fitzgerald raised its FY2025 EPS estimate to $23.25 and maintained an “Overweight” rating Cantor Fitzgerald Brokers Raise Earnings Estimates for LLY
• Positive Sentiment: JPMorgan reaffirmed its Overweight rating with an $1,100 price target JPMorgan Maintains ‘Overweight’ Rating on Eli Lilly and Company (LLY) With $1,100 PT
• Positive Sentiment: DZ Bank upgraded LLY from “Hold” to “Strong Buy” Eli Lilly and Company (NYSE:LLY) Upgraded to "Strong-Buy" at DZ Bank
• Positive Sentiment: Q2 results beat consensus with 38% revenue growth driven by Zepbound and Mounjaro, and full-year guidance was raised Eli Lilly and Company (LLY) Releases Q2 2025 Results
• Neutral Sentiment: Lilly and Novo Nordisk launched cash-pay programs targeting self-pay U.S. GLP-1 customers Eli Lilly (LLY) and Novo Nordisk Target Cash-Pay Customers
• Neutral Sentiment: Featured by MarketBeat and others among pharmaceutical stocks worth watching today Pharmaceutical Stocks To Consider - August 17th
• Neutral Sentiment: Included in a dividend growth stock roundup by 247 Wall Street 2 Phenomenal Dividend Growth Stocks That Insiders Are Buying Hand Over Fist
• Neutral Sentiment: Positioned as the stable large-cap in the “Ozempic wave” narrative alongside smaller peers Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets
• Negative Sentiment: Novo Nordisk halved the U.S. price of Ozempic to $499/month, intensifying pricing pressure in the GLP-1 market Novo Nordisk halves US price of Ozempic - Financial Times
• Negative Sentiment: Disappointing obesity-pill data for orforglipron weighed on sentiment, contributing to a 5% monthly decline Lilly Stock Down 5% This Month: Should You Buy the Dip?
• Negative Sentiment: Tariff threats led Lilly to raise Mounjaro prices in the U.K., which may dampen demand offshore Trump tariff threat pushes Eli Lilly to raise Mounjaro prices in UK